The ATAD1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from HT29 colorectal adenocarcinoma cells, in which the ATAD1 gene has been disrupted to establish a loss-of-function model. This product provides a genetically defined tool for studying ATAD1-mediated processes in a human intestinal epithelial cell context. The polyclonal nature of the knockout population ensures representation of diverse editing events, facilitating robust functional analyses without the need for single-cell cloning.
HT29 is a well-characterized human colorectal adenocarcinoma cell line that retains many features of intestinal epithelial cells, including polarization and the ability to differentiate under appropriate conditions. Widely employed in oncology and drug permeability studies, HT29 cells offer a relevant in vitro system for exploring tumor biology, cell signaling, and therapeutic responses. Their use as the host line for ATAD1 knockout provides a platform to interrogate mitochondrial quality control mechanisms within a cancer cell context.
ATAD1 encodes a mitochondrial outer membrane AAA+ ATPase that functions as a key regulator of proteostasis by extracting mistargeted tail-anchored proteins from the membrane in an ATP-dependent manner. This activity prevents the aberrant accumulation of proteins such as BNIP3 and BNIP3L, which are pro-apoptotic factors whose mislocalization can trigger mitochondrial damage. ATAD1 operates within a broader network involving DRP1-mediated fission, MFN1/2-driven fusion, and the PINK1/Parkin pathway, and its homohexameric structure enables substrate recognition and dislodgement. Through these interactions, ATAD1 directly influences mitochondrial morphology and quality control, acting upstream of Mff and other tail-anchored substrates.
In the context of HT29 colorectal adenocarcinoma cells, ATAD1 disruption provides a means to dissect the intersection between mitochondrial quality control and oncogenic processes. Colorectal cancer cells often exhibit altered mitochondrial dynamics and metabolic reprogramming, and the loss of ATAD1 may exacerbate mitochondrial fragmentation and apoptosis susceptibility. This model thus enables the investigation of how mitochondrial proteostatic failure contributes to tumor progression, drug resistance, or sensitivity to apoptosis-inducing agents, making it relevant for both basic cancer biology and translational studies.
Researchers can employ these ATAD1 knockout cells to explore mitochondrial dysfunction in colorectal cancer through assays such as BNIP3/BNIP3L Western blotting, immunofluorescence for mitochondrial morphology, and Seahorse metabolic flux analysis. Functional studies may include apoptosis and migration/invasion assays to assess how ATAD1 loss impacts cell survival and metastatic behavior. Additionally, these cells can serve as a surrogate model for investigating ATAD1-related neurological disorders, given the gene’s conserved role in mitochondrial quality control. Drug sensitivity screening can further identify compounds that modulate mitochondrial stress responses. For further details and technical support, please contact Ascent Research.
